Clinical trial / 2021
In patients with alcohol-related cirrhosis, fecal microbiota transplant reduced alcohol craving and serious adverse events compared with placebo.
Twenty men with alcohol use disorder-related cirrhosis were randomized 1:1 to receive a single placebo or fecal microbiota transplant (FMT) enema from a donor enriched in Lachnospiraceae and Ruminococcaceae. At day 15, craving was reduced in 90% of the FMT group versus 30% in placebo (P = 0.02), accompanied by lower urinary ethylglucuronide/creatinine (P = 0.03), improved cognition and psychosocial quality of life, reduced IL-6, and increased microbial diversity and butyrate/isobutyrate. Over 6 months, patients with serious adverse events (SAEs) were significantly higher in placebo compared to FMT (8 vs. 2, P = 0.02), as were AUD-related SAEs (7 vs. 1, P = 0.02).
- Study type
- Phase 1 double-blind randomized placebo-controlled trial
- Who was studied
- 20 men with AUD-related cirrhosis and problem drinking (mean age 65 ± 6.4 years)
- What was measured
- 6-month safety, alcohol craving, alcohol consumption, quality of life, cognition, serum IL-6, LPS-binding protein, SCFAs, stool microbiota, and serious adverse events
THE PAPER
A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder.
Bajaj JS, Gavis EA, Fagan A, Wade JB, Thacker LR, Fuchs M, Patel S, Davis B, Meador J, Puri P, Sikaroodi M, Gillevet PM. Hepatology, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.